Abstract:This article describes the main conclusions drawn from the presentations on Helicobacter pylori infection in Digestive Diseases Week, 2016. Despite the undeniable widespread reduction in the prevalence of this infection, infection rates continue to be high in developing countries. The prevalence of clarithromycin, metronidazole and quinolone resistance is markedly high in most countries and continues to rise. The management of H. pylori infection in patients with peptic ulcers still leaves much to be desired. Although H. pylori eradication reduces the incidence of gastric adenocarcinoma, it does not completely avoid its appearance. The new rapid stool antigen tests show promising results. The efficacy of standard triple therapy is clearly inadequate and continues to decline, and cannot therefore be recommended. Vonoprazan, when associated with 2 antibiotics, is more effective than traditional proton pump inhibitors, especially in clarithromycin-resistant patients. Non-bismuth quadruple (concomitant) therapy achieves eradication rates of around 90% and has a good safety profile. Concomitant therapy is more effective and simpler than sequential therapy. Although some probiotics can increase the efficacy and tolerability of triple therapy, the utility of its association with quadruple concomitant therapy has not been established. If a first treatment with clarithromycin fails, both bismuth-containing quadruple therapy and levofloxacin-containing triple therapy achieve good-but still suboptimal-results. The combination of bismuth and levofloxacin in the same regimen increases the efficacy of rescue therapy. The management of H. pylori infection by European gastroenterologists is widely heterogeneous and the eradication rates achieved by them are generally unacceptable. In Spain, the highest first-line eradication rate is obtained with quadruple concomitant therapy in 14-day regimens and with double doses of proton pump inhibitors; in second-line therapy, the use of levofloxacin- and bismuth-containing quadruple therapy improves the rates traditionally obtained with quinolones. On the other hand, there is a clear disconnect between the recommendations made in consensus documents and clinical practice in primary care.

Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report

Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report

Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

Historical Overview of the Maastricht Consensus Reports for the Management of Helicobacter Pylori Infection. Where are we Today?

Treatment of Helicobacter pylori infection: A clinical practice update

Helicobacter pylori Infection: New Facts in Clinical Management

Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection

Management of Helicobacter pylori-related disorders

Treatment of Helicobacter pylori infection: a clinical practice update.

Best Practice Recommendations for Diagnosis and Management of Helicobacter pylori—Synthesizing the Guidelines

The Main Statements of the Consensus “Maastricht-VI” (2022) on the Diagnostics and Treatment of Helicobacter pylori Infection

Helicobacter Pylori Infection: A Recent Approach to Diagnosis and Management

Helicobacter pylori World Gastroenterology Organization Global Guideline

Current and Future Treatment of Helicobacter pylori Infections

The second Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of Helicobacter pylori infection in adult patients in Ireland

Room for Improvement in the Treatment of Helicobacter pylori Infection

Eradication of Helicobacter pylori: recent advances in treatment

Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology

Kyoto global consensus report on Helicobacter pylori gastritis

Helicobacter pylori-related diseases